Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?

Harmony Biosciences (HRMY) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Sep 3, 2026

Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress

PLYMOUTH MEETING, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore data from the company's investigation of EPX-100 (clemizole hydrochloride) at the 16th European Epilepsy Congress being held from September 5-9, in Athens, Greece.

GlobeNewsWire • Sep 3, 2026

Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference

PLYMOUTH MEETING, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York, N.Y., on Thursday, September 10, 2026, at 10:20 a.m., E.T.

GlobeNewsWire • Aug 27, 2026

Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline

Harmony Biosciences NASDAQ: HRMY highlighted record quarterly performance for its narcolepsy treatment WAKIX and outlined development plans across its orexin, epilepsy and pitolisant lifecycle-management programs during Piper Sandler's virtual CNS Symposium.

MarketBeat • Aug 14, 2026

4 Healthcare Stocks to Watch as Defensive Demand Strengthens

Healthcare's defensive demand is strengthening in 2026. BTSG, HRMY, UNH and NVCR stand out on improving earnings outlooks and steady sector momentum.

Zacks Investment Research • Aug 7, 2026

Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium

PLYMOUTH MEETING, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the Piper Sandler Virtual CNS Symposium on Thursday, August 13, 2026, at 1:30 p.m. ET.

GlobeNewsWire • Aug 6, 2026

HRMY Q2 Earnings Beat Estimates on Strong Wakix Sales, Stock Up

HRMY tops Q2 estimates as Wakix demand fuels 30% revenue growth. A growing pipeline, BP-205 progress and reaffirmed 2026 guidance add momentum.

Zacks Investment Research • Aug 5, 2026

Here is Why Growth Investors Should Buy Harmony Biosciences (HRMY) Now

Harmony Biosciences (HRMY) could produce exceptional returns because of its solid growth attributes.

Zacks Investment Research • Aug 5, 2026

Harmony Biosciences: Management Raised Its Game, But The Stock Has Already Rerated

Harmony Biosciences Holdings, Inc. has now elevated BP-205, its orexin-2 receptor agonist, to lead the pipeline. HRMY management has become even more specific about business development—exactly the kind of thing I thought was missing earlier. My updated valuation suggests most of the improvement is now reflected in the stock. I am, therefore, upgrading HRMY from Sell to Hold.

Seeking Alpha • Aug 5, 2026

Harmony Biosciences Q2 Earnings Call Highlights

Harmony Biosciences NASDAQ: HRMY reported second-quarter net revenue of $261.3 million, up 30% from the prior-year period and 21% sequentially, as sales of its narcolepsy treatment WAKIX rebounded from seasonal market-access pressures earlier in the year.

MarketBeat • Aug 4, 2026